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Abstract
Oxysterol sulfation plays an important role in regulation of lipid metabolism and inflammatory responses. In the present
study, we report the discovery of a novel regulatory sulfated oxysterol in nuclei of primary rat hepatocytes after
overexpression of the gene encoding mitochondrial cholesterol delivery protein (StarD1). Forty-eight hours after infection of
the hepatocytes with recombinant StarD1 adenovirus, a water-soluble oxysterol product was isolated and purified by
chemical extraction and reverse-phase HPLC. Tandem mass spectrometry analysis identified the oxysterol as 5-cholesten-3b,
25-diol, disulfate (25HCDS), and confirmed the structure by comparing with a chemically synthesized compound.
Administration of 25HCDS to human THP-1-derived macrophages or HepG2 cells significantly inhibited cholesterol synthesis
and markedly decreased lipid levels in vivo in NAFLD mouse models. RT-PCR showed that 25HCDS significantly decreased
SREBP-1/2 activities by suppressing expression of their responding genes, including ACC, FAS, and HMG-CoA reductase.
Analysis of lipid profiles in the liver tissues showed that administration of 25HCDS significantly decreased cholesterol, free
fatty acids, and triglycerides by 30, 25, and 20%, respectively. The results suggest that 25HCDS inhibits lipid biosynthesis via
blocking SREBP signaling. We conclude that 25HCDS is a potent regulator of lipid metabolism and propose its biosynthetic
pathway.
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lates cholesterol efflux and clearance via activation of LXR and
subsequently increasing gene expression of ATP-binding cassette
subfamily A1 (ABCA1) and G5/8 (ABCG5/8) in the liver [7,8].
On the other hand, LXR activation up-regulates the expression of
SREBP-1c, which in turn up-regulates at least 32 genes involved in
lipid biosynthesis and transport [9]. Therefore, LXR activation
could have a profound effect on serum cholesterol levels, but its
inappropriate activation of SREBP-1c could lead to hepatic
steatosis and hypertriglyceridemia due to the elevated fatty acid
and triglyceride synthesis [10].
Oxysterol sulfation as a regulatory pathway has grown out of a
series of studies in the past seven years, including discovery of a
novel oxysterol sulfate, identification of a key enzyme hydroxysterol sulfotransferase 2B1b (SULT2B1b) in oxysterol sulfate
biosynthesis, and investigation into the role of oxysterol sulfates in
regulation of lipid metabolism, inflammatory responses, and cell
proliferation [11]. The previous report has shown that bile acid
biosynthesis via the acidic, ‘‘alternative’’, pathway was limited by
mitochondrial cholesterol uptake. This barrier could be overcome
by increasing expression of the mitochondrial cholesterol transporter StarD1. This suggests a physiological role for StarD1.
Increases in StarD1 expression also led to up-regulation of biliary
cholesterol secretion and downregulation of cholesterol, fatty acid,
and triglyceride biosynthesis [12,13,14,15], and inhibition of

Introduction
Intracellular lipid accumulation, inflammatory responses, and
apoptosis are the major pathogenic events of many metabolic
disorders, including atherosclerosis and nonalcoholic fatty-liver
diseases (NAFLD). Increasing evidence shows that nuclear
receptors play critical roles in the regulation of lipid metabolism
and inflammatory responses [1,2]. Nuclear receptors are ligandactivated transcription factors that affect processes as diverse as
reproduction, development, inflammation, and general metabolism through regulating target gene expression. Many nuclear
receptors function as sensors of cellular cholesterol and lipid levels,
and elicit gene-expression changes that maintain lipid homeostasis
and protect cells from lipid overload. Examples include receptors
for fatty acids (peroxisome proliferator activated receptors, PPARs)
[3,4], oxysterols (liver X receptors, LXRs), bile acids (farnesoid X
receptor, FXR), and retinoic acids (retinoic acid receptors, RXRs).
In many cases, however, their natural ligands—such as orphan
nuclear receptors—remain unknown. To further identify authentic
lipid ligands of nuclear orphan receptors becomes more and more
important.
Oxysterols play an important role in maintenance of cholesterol
homeostasis and lipid metabolism [5,6]. Oxysterols suppress
cholesterol biosynthesis through degradation of mRNA of 3hydroxy-3-methylgutaryl-CoA reductase (HMGCR) and stimuPLOS ONE | www.plosone.org
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inflammation and apoptosis [16,17]. A search for these regulatory
effects’ mechanisms led to the discovery of a novel sulfated
oxysterol, 5-cholesten-3b, 25-diol, 3-sulfate (25HC3S) with potent
regulatory properties [18,19]. The results imply that StarD1 serves
as a sensor for high levels of intracellular cholesterol. StarD1
delivers cholesterol into mitochondria for biosynthesis of regulatory oxysterols, which maintenances lipid homeostasis [18,11].
25HC3S can be biosynthesized by sterol sulfotransferase
SULT2B1b using 25-hydroxycholesterol (25HC) as the substrate
via oxysterol sulfation [20]. Functional studies have shown that
this regulatory pathway plays an important role in lipid
metabolism, inflammatory responses, and cell proliferation
through
regulating
nuclear-receptor
activity
[19,21,22,23,24,25,26]. All the established studies indicate that
oxysterol sulfation is a novel regulatory pathway in regulation of
lipid metabolism, inflammation, and cell proliferation.
Exogenous administration of 25HC3S decreases both SREBP1c and SREBP-2 expression, blocks the SREBP-1c processing,
represses the expression of key enzymes including acetyl-CoA
carboxylase-1 (ACC-1), fatty acid synthase (FAS) and HMGR in
lipid metabolism, subsequently decreases intracellular neutral lipid
and cholesterol levels [19,21,22,27]. The results indicate that
25HC3S appears to act as a LXR antagonist and as a cholesterol
satiety signal, suppressing fatty acid and triglyceride biosynthesis
via inhibiting LXR/SREBP pathway [21]. Moreover, 25HC3S
increases IkBa expression, blocks TNFa-induced IkBa degradation, and decreases nuclear NFkB level. In contrast, 25HC acts in
an opposite manner: inducing IkBa degradation and NFkB
nuclear translocation [22,24]. These results indicate that 25HC3S
is also involved in inflammatory responses, which may represent a
link between inflammatory pathways and the regulation of lipid
homeostasis via oxysterol sulfation.
In the present study, we identified another novel sulfated
oxysterol, 5-cholesten-3b,25-diol, disulfate (25HCDS). Administration of 25HCDS substantially increased expression of genes
encoding PPARc, PPARc coactivator 1 alpha (PGC-1a), and IkB,
and decreased hepatic triglyceride and cholesterol levels by
suppressing LXR-SREBP-1c/SREBP-2 signaling pathway in
mouse NAFLD models. These findings provide strong evidence
that 25HCDS is another potent regulator involved in lipid
metabolism and inflammatory responses.

Characterization of Novel Cholesterol Metabolite
Adenovirus Preparation and Propagation. The adenovirus construct used in this study was obtained through the Massey
Cancer Center Shared Resource Facility of the Virginia Commonwealth University as previously described [28].
Cell Culture and Nuclear Fraction of Primary Rat
Hepatocytes Isolation and Lipids Extraction. Primary rat

hepatocyte (PRH) cultures, prepared as previously described [18],
were seeded on 150 mm tissue culture dishes (,2.56107 cells) in
Williams’ E medium containing dexamethasone (0.1 mM). Cells
were maintained in the absence of thyroid hormone. Twenty-four
hours after plating, culture medium was removed, and 4 ml of
fresh medium was added. Cells were then infected with
recombinant adenovirus encoding either the StarD1 cDNAs
followed the human cytomegalovirus (CMV) promoter (AdCMV-StarD1) or no cDNA, as a control virus. The viruses were
allowed to incubate for 2 hrs in minimal culture medium with
gentle shaking of the plates every 15 minutes. After 2 hrs of
infection, unbound virus were removed and replaced with 20 ml
of fresh medium. After 48 hrs, cells were then harvested and
processed for nuclear isolation as described [28]. Briefly, cells were
disrupted by Dounce homogenization in buffer A (10 mM
HEPES-KOH at pH 7.6, 1.5 mM MgCl2, 10 mM KCl,
0.5 mM dithiothreitol, 1 mM sodium EDTA, 1 mM EGTA)
and spun at 1,0006 g for 10 mins. The nuclear pellet was further
fractionated by resuspension in 2.5 ml of a 1:1 mixture of buffer A
and buffer B (2.4 M Sucrose, 15 mM KCl, 2 mM sodium EDTA,
0.15 mM spermine, 0.15 mM spermidine, 0.5 mM dithiothreitol)
and centrifuged at 100,0006 g for 1 hr at 4uC through a 1 ml
cushion of 3:7 mixture of buffer A and B. The washed nuclear
pellet was resuspended in buffer A containing 0.5% (v/v) nonidet
P-40 and centrifuged at 10006 g for 10 min at 4uC. The
supernatant is designated as purified nuclei.
The purified nuclei were re-suspended and digested by 2 mg/
ml of DNase I in 50 mM of acetic buffer, pH 5.0, 10 mM MgCl2
at 37uC for 2 hrs. After centrifugation at 10,0006 g for 20 mins,
the pellets were further digested by 2 mg/ml of proteinase K in
phosphate buffered saline solution (PBS) at 50uC for 16 hrs. Total
lipids in the digests were extracted by adding 3.3 volumes of
chloroform:methanol (1:1) and separated into two phases,
methanol/water and chloroform phases as previously described
[29].

Materials and Methods

HPLC Analysis of Cholesterol Derivatives in Methanol/
Water Phase. Total lipid extracts in methanol/water phases

Materials

were analyzed on an Ultrasphere PTH C-18 column
(5 m64.6 mm625 cm; Backman, USA) at 0.8 ml/min flow rate.
The column was equilibrated and run in 20 mM KH2PO4,
pH 4.2:acetonitrile:methanol (1:3:6, v/v/v) as the mobile phase.
The effluents were monitored at 195 nm and collected every
0.5 min (0.4 ml per fraction) except as indicated. The column was
calibrated with tauroursodeoxycholic acid, glycoursodeoxycholic
acid, taurocholic acid, glycocholic acid, taurochenodeoxycholic
acid, taurodeoxycholic acid, and progesterone.
Purification of Sulfated Oxysterols. Sulfated oxysterols
were further purified from liver lipid extracts in the methanol/
water phases. The extracts were dried under nitrogen stream and
dissolved in 50% phosphate buffer saline (PBS) in acetonitrile
(loading buffer). The solution was passed through Oasis Wax 6cc
Cartridge. The column was washed with 10 volumes of the loading
buffer, 10 volumes of water, 10 volumes of methanol, 2 volumes of
10% methanol in water, and 5% NH4OH in 10% methanol. The
sulfated oxysterols were eluted by 3 ml of 5% NH4OH in 80%
methanol and analyzed by LC/MS/MS.

Cell culture reagents and supplies were purchased from GIBCO
BRL (Grand Island, NY); 25-hydroxycholesterol from New
England Nuclear (Boston, MA). THP-1 and HepG2 cells were
obtained from American Type Culture Collection (Rockville,
MD). The reagents for real time RT-PCR were from AB Applied
Biosystems (Warrington WA1 4 SR, UK). The chemicals used in
this research were obtained from Sigma Chemical Co. (St. Louis,
MO) or Bio-Rad Laboratories (Hercules, CA). Polyclonal rabbit
antibodies against SREBP-1, SREBP-2, and HMG-CoA reductase
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
All solvents were obtained from Fisher (Fair Lawn, NJ) unless
otherwise indicated. The enhanced chemiluminescence (ECL)
reagents were from Amersham Biosciences (Piscataway, NJ).
OasisHWax Cartridges were purchased from Waters Corporation
(Milford, MA). The testosterone and 27-hydroxycholesterol were
obtained from Research Plus Inc. (Bayonne, NJ). LK6 20620 cm
normal phase thin layer chromatography (TLC) plates were
purchased from Whatman Inc. (Clifton, NJ).

PLOS ONE | www.plosone.org
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Reverse Phase Liquid Chromatography/Tandem Mass
Spectrometry/Mass Spectrometry (LC/MS/MS) Analysis
of Sulfated Oxysterols. Samples to be analyzed were consti-

25HCDS as indicated for 6 hrs, cells in 60 mm dishes were given
3 ml of the same fresh medium containing 5 mCi of [1-14C]
acetate. After 2 hr incubation at 37uC, the media was removed.
The cells were washed twice with phosphate-buffered saline (PBS),
harvested with rubber police as described, and collected in
microcentrifuge tubes. The cells were sedimented by centrifugation, and the pellets were washed three times by resuspension and
sedimentation. The cellular pellets were resuspended in 0.3 ml of
PBS. The total lipids were extracted and separated by adding 3
volumes of chloroform:methanol (1:1) as previously described [18].
[14C] Cholesterol and hydroxycholesterols were isolated into
chloroform phase and separated on TLC (toluene:acetyl acetate,
2/3, v/v/). [1-14C] acetate derivatives were visualized by Image
Reader, Fujifilm BAS-1800 II as previously described [19].
[1-14C] Acetate derivatives in the chloroform phase were
analyzed by HPLC on an Ultrasphere Silica column
(5 mm64.6 mm625 cm; Backman, USA) using HP Series 1100
solvent delivery system (Hewlett Packard) at 1.3 ml/min flow rate.
The column was equilibrated and run in a solvent system of
hexane:isopropanol:glacial acetic acid (965:25:10, v/v/v), as the
mobile phase. The effluents were collected every 0.5 min (0.65 ml
per fraction) except as indicated. The counts in [14C] acetate
derivatives were determined by Scintillation Counting. The
column was calibrated with [14C] cholesterol, [3H]25-hydroxycholesterol, and [14C] 27-hydroxycholesterol.

tuted in methanol:water (20:80, v/v) and separated on a
ThermoKeystone Aquasil C18 column (5 mm, 2.1 mm6100 mm).
The mobile phase was consisted of (A), 0.1% formic acid in water,
and (B), 0.1% formic acid in acetonitrile. The 20 min gradient was
as follows: 0–10.0 min, 10%–95% B linear; 10.0–15.0 min, 95%
B; 15.0–15.1 min, 95%-10% B linear; 15.1–20.0 min, 10% B.
The elution stream (0.3 ml/min) from the HPLC apparatus was
introduced into a MDS Sciex ABI 4000 Triple Quadrapole Mass
Spectrometer (MDS Sciex, Toronto, Canada) with a Turbo Ion
Spray ionization (ESI) source for the analyses. The mass
spectrometer was operated in negative ion modes, and data were
acquired using both full scan mode as well as the product ion
mode for MS/MS (Core Facility, Virginia Commonwealth
University School of Pharmacy).

Chemical Synthesis of 5-Cholesten-3b, 25-Diol, Disulfate
Synthesis of 5-cholesten-3b,25-diol-disulfate (25HCDS): To a
solution of the 25-hydroxycholesterol (80 mg, 0.14 mmol) in
anhydrous pyridine (800 mL), sulfur trioxide–trimethylamine
complex (133 mg, 0.95 mmol) was added, and the suspension
was stirred at 50uC at room temperature overnight. To the
reaction mixture, 2 ml of acetonitrile were added and evaporated
to dryness under N2 stream. The pellets were dissolved in 2 ml of
50% PBS, pH 7.2, in acetonitrile (loading buffer) applied to a 6 cc
Oasis cartridge (Waters), which had been primed by methanol
(15 mL) and water (15 mL). The cartridge was successively
washed with the loading buffer (15 ml), methanol (15 mL), 10%
methanol (5 ml), and 5% ammonia hydroxide in 10% methanol
(15 ml). The retained 25HCDS was eluted with 5% ammonia
hydroxide in 60% methanol (10 ml). After dilution with 10 times
volume of acetonitrile, the solvents were evaporated to dryness
under N2 stream, and the 25HCDS was obtained as powdered
form. Yield was about 70 mg (,70%).
1
H and 13C NMR spectra were obtained on a Varian 500 Inova
(AS500) instrument at 499.62 MHz and 125.64 MHz, respectively. Flow injection low-resolution mass (LR-MS) spectra were
recorded by a Thermo Scientific TSQ Quantum Ultra MS
equipped with electrospray ionization (ESI) probe under negative
ion mode. Reversed-phase TLC was carried out on pre-coated
RP-18F254S plates using methanol–water–acetic acid mixtures
(89:10:1, v/v/v) as the developing solvent. The spots were
visualized by 50% H2SO4 with heating at 110uC.

Determination of mRNA Levels by Real-Time RTPCR. Total RNA was isolated with SV Total RNA Isolation

Kit (Promega, Madison, WI), which included DNase treatment.
Total RNA, 2 mg, was used for the first-strand cDNA synthesis as
recommended by the manufacturer (Invitrogen, Carlsbad, CA).
Real-time RT-PCR was performed using SYBR Green as
indicator on ABI 7500 Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA). Amplifications of b-actin and
GAPDH were used as internal controls. Relative messenger
RNA (mRNA) expression was quantified with the comparative
cycle threshold (Ct) method and was expressed as 22DDCt as
describe before [30].
In vivo Study using Fatty Liver Animal Model. Animal
studies were approved by Institutional Animal Care and Use
Committee of McGuire Veterans Affairs Medical Center and were
conducted in accordance with the Declaration of Helsinki, the
Guide for the Care and Use of Laboratory Animals, and all
applicable regulations. To examine the effect of 25HCDS on dietinduced lipid accumulation in sera and liver, 8-week-old female
C57BL/6J mice (Charles River, Wilmington, MA) were fed high
fat diet (HFD) (Harlan Teklad, Madison, WI) containing 42% kcal
from fat, 43% kcal from carbohydrate, 15% kcal from protein and
0.2% cholesterol for 16 weeks and changed to normal diet three
days before the end period as previously reported [23]. All mice
were housed under identical conditions in an aseptic facility and
given free access to water and food. After 10-week’s HFD feeding
the mice were intraperitoneally injected with vehicle solution
(ethanol/PBS) or 25HCDS (25 mg/kg) twice a week for 6 weeks.
At the end of the experiment, all mice were fasted overnight before
blood and liver samples were collected. Triglyceride, total
cholesterol, high density lipoprotein-cholesterol, glucose, alkaline
phosphatase (ALK), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in sera were measured using standard
enzymatic techniques in the clinical laboratory at McGuire
Veterans Affairs Medical Center.
Quantification of hepatic lipids. Liver tissues were homogenized, and lipids were extracted with a mixture of chloroform
and methanol (2:1) and filtered. The extracts, 0.2 ml, were
evaporated to dryness and dissolved in 100 ml of isopropanol

Functional Studies
Cell Culture. Human THP-1 monocytes and HepG2 cells
were maintained according to the supplier’s protocols. THP-1
monocytes were differentiated to macrophages by adding 100 nM
of phorbol 12-myristate 13-acetate (PMA) for 5 days. When cells
reached ,90% confluence, 25HCDS in ethanol (the final
concentration of ethanol in media was 0.1%) was added. The
cells were harvested at the indicated times for protein, mRNA, and
lipid analysis.
For study of HMG CoA reductase expression regulation,
HepG2 or THP-1 were cultured in the media as described above
in the presence or absence of mevinolin (50 mM) and mevalonate
(0.5 mM). After culturing for 48 hrs, oxysterols were added and
cultured for another 6 hrs. The cells were harvested for
determining mRNA levels.
Determination
of
Cholesterol
Biosynthesis
by
TLC. After incubation of THP-1 derived macrophages or

HepG2 cells in media containing different concentrations of
PLOS ONE | www.plosone.org
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Figure 1. Characterization of nuclear oxysterol as 5-cholesten-3b, 25-diol disulfate by negative ion-triple quadruple mass spectrometry.
Forty-eight hours following the indicated recombinant adenovirus infection, cells were harvested. Nuclear fraction was isolated and extracted by the Folch
method. The lipids in the methanol/water phase were analyzed by HPLC by monitoring at 195 nm (Panel A). In each case, the nuclear methanol/water
extracts of the equivalent of 56106 cells were loaded. The elution profiles represent one of the five sets of experiments (the profiles are highly repeatable).
HPLC/MS negative full scan spectrum, HPLC-MS elution profile sorted with mass ion 80, of extract from primary rat hepatocyte is shown in Panel B. The MSMS product spectrum of the mass 561 and its fragmentation diagrams are shown in Panel C. The product spectrum of mass ion 583 is similar to that of 561
(data not shown). Each fragment represents negative ion of the chemical structure fragments m/z 561 and m/z 583.
doi:10.1371/journal.pone.0103621.g001
PLOS ONE | www.plosone.org
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Figure 2. Analysis of chemically synthesized 25HCDS: MS spectrum and 1H NMR spectrum of 25HCDS. (A) Negative ion flow injection
mass spectrum of 25HCDS. m/z, 583(M+Na-2H), 561 (M-H) 481 (M-S) and 463 (M-S-S-H2O) were observed as major ions. This fragmentation pattern is
similar to that obtained from the nuclear compound (Fig. 1C); (B) 1H NMR spectrum of 25HCDS; the sulfated 3a-H resonated at 4.14 ppm which was
ca 0.7ppm downfield compared to that of unsulfated 3a-H in 25HC. All other chemical shifts and their spin couplings observed were similar to those
of 25HC and 25HC3S; and (C) 13C NMR spectrum of 25HCDS; the C-3 and C-25 resonated at 86 and 80 ppm, which were d 14 ppm and d 9 ppm
downfield, respectively, indicating that both positions are sulfated.
doi:10.1371/journal.pone.0103621.g002

PLOS ONE | www.plosone.org
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Figure 3. Effects of 25HCDS on lipid metabolism in HepG2 cells. After incubation of the 25HCDS-treated HepG2 cells with [1-14C] acetate for
2 hrs, the total neutral lipids were extracted and Folched. [14C]-Counts (neutral lipids) in methanol and chloroform phases are shown in Panel A. TLC
analysis of the [14C]-acetate derivatives extracted from the equivalent of 56106 cells per each lane is shown in Panel B, where the Xol represents
cholesterol; the [14C]-acetate derivative cholesterol was further relatively quantitated by HPLC. The column was calibrated by standards
[14C]cholesterol, [14C]27-hydroxycholesterol, and [3H]25-hydroxycholesterol. HPLC analysis of the [14C]-acetate derivatived cholesterol is shown in
Panel C. Real time RT-PCR analysis of SREBP-2 and HMG CoA reductase in HepG2 cells treated with 25HCDS at indicated time is shown in Panel D;
SREBP-1c, ACC, and FAS mRNA levels, at indicated concentration, are shown in Panel E; SREBP-2, HMG-CoA reductase, and LDLR are shown in Panel
F. The expression levels were normalized toGAPDH. Each value represents mean of three measurements.
doi:10.1371/journal.pone.0103621.g003

containing 10% of triton X-100 for cholesterol assay (Wako
Chemicals USA, Richmond, VA), NEFA solution (0.5 g of EDTANa2, 2 g of Triton X-100, 0.76 ml of 1N NaOH, and 0.5 g of
PLOS ONE | www.plosone.org

sodium azide/l, pH 6.5) for free fatty acid assay (Wako Chemicals
USA, Richmond, VA), or isopropanol only for triglyceride assay
(Fisher Scientific, Pittsburgh, PA), respectively. All of the assays
6
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Figure 4. 25HCDS decreases serum lipid levels and improves liver function in mouse NAFLD models. Eight-week-old C57BL/6J female
mice treated with either 25HCDS or vehicle every three days for six weeks and fasted overnight. Plasma triglyceride, total cholesterol, and highdensity lipoprotein (HDL), alkaline phosphatase (ALK), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were determined. All the
data are expressed as mean 6 SD with p value when 25HCDS treated versus vehicle-treated mice liver.
doi:10.1371/journal.pone.0103621.g004

were performed according to the manufacturer’s instructions.
Each lipid concentration was normalized to total protein of liver.
Statistics. Data are reported as the mean 6 standard
deviation. Where indicated, data were subjected to t-test analysis
and determined to be significantly different if p,0.05.

bigger molecules are very similar (data not shown). Fragment ions
were observed at m/z = 97, 463, and 481 in the product scan
spectrum of m/z 561 (Fig. 1C). These observed fragment ions
indicate that the nuclear oxysterol is a disulfated oxysterol with a
sulfate group on 3-OH and 25 position (18) and a hydroxyl group
on side chain, m/z 59, (molecular mass 562 = 160 (disulfate)+16
(O)+386 (cholesterol). Referenced with the data from previous
reports [18], the nuclear oxysterol derivative was assumed as 5cholesten-3b, 25-diol disulphate (25-hydroxycholesterol 3,25disulfate, 25HCDS) (Fig. 1C). This structure has been further
confirmed by chemically synthesized 25HCDS as stated below.

Results
Analysis of the lipid composition in the methanol/water phases
extracted from nuclear fractions following overexpression of
StarD1 protein showed a unique peak with retention times at
11.5 min in HPLC elution profile (Fig. 1A). The results are
consistent with previous reports, and the peak was believed to be
cholesterol metabolites [18]. To further characterize the chemical
structure of the peak, the HPLC purified cholesterol metabolites
were analyzed by liquid chromatography-tandem mass spectrometry (LC/MS/MS). The LC/MS Q1 full scan spectrum sorted
with m/z 80 showed two bigger molecule ions, m/z 561 and 583
and two major molecular ions 480 and 481 (Fig. 1B). The latter
two ions have been characterized as 25HC3S [18]. These two
molecular ions were further analyzed by HPLC/MS-MS under
negative ionization mode. The product scan of m/z 561 has been
shown in Fig. 1C. The characteristic fragment ions of these two
PLOS ONE | www.plosone.org

Chemical Synthesis of the Nuclear Oxysterol, 5-cholesten3b, 25-diol, Disulfate
To confirm its structure and study its role in cellular lipid
homeostasis and inflammatory responses, 25HCDS was chemically synthesized and purified. MS analysis of the synthesized
compound shows the same molecular mass ion, m/z 561 and m/z
583 (+Na) as the authentic nuclear oxysterol, and the purified
product was not contaminated by the starting material, 25hydroxycholesterol, m/z 401. LR-MS (ESI-negative), m/z: 583.4
(M+Na-2H, 88%), 561.3 (M-H, 46%), 481.4 (M-SO3-H, 11%),
7
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Figure 5. 25HCDS decreases lipid accumulation in the liver tissue in mouse NAFLD models. Animals were peritoneal-injected with
25HCDS once every 3 days for 6 weeks. Hepatic triglyceride, free fatty acid, total cholesterol, free cholesterol, cholesterol ester, free fatty acid, and
triglyceride were determined as described in Methods. Each individual level was normalized by protein concentration. All the data are expressed as
mean 6 SD with p value when 25HCDS treated versus vehicle-treated mice liver.
doi:10.1371/journal.pone.0103621.g005

463.4 (M-H2SO4-H, 34%), 431.82 (14%), 381.27 (100%)
(Fig. 2A). 1H NMR (CD3OD) d: 0.72 (3H, s, 18-CH3), 0.97
(3H, d, J 5.0 Hz, 21-CH3), 1.03 (3H, s, 19-CH3), 1.14 (6H, s, 26and 27-CH3), 4.14 (1H, br. m, 3a-H), 5.39 (1H, br. s, 6-H)
(Fig. 2B). 13C NMR (CD3OD) d: 12.45, 19.37, 19.90, 21.82,
22.29, 25.45, 25.51, 27.05, 27.12, 29.39, 29.44, 30.13, 33.16,
33.37, 37.26, 37.32, 37.50, 38.60, 40.52, 41.27, 43.65, 51.78,
57.71, 58.37, 79.98, 85.93, 123.44, 141.71 (Fig. 2C). The results

indicate that the synthesized molecule is 5-cholesten-3b, 25-diol,
disulphate (25HCDS) and matches the molecule found in the
hepatocyte nuclear fraction.

25HCDS Inhibits Lipid Biosynthesis at Transcriptional
Levels
To examine the effects of 25HCDS on cholesterol biosynthesis,
the rates of cholesterol synthesis were determined. The effects of

Table 1. Relative Hepatic mRNA Expression Involved in Lipid Metabolism in Mice Fed on a HFD with or without 25HCDS.

Gene Name

Gene description

HFD (n = 6)

HFD+25HCDS (n = 7)

SREBP-1c

Sterol regulatory element-binding protein-1c

1.060.36

0.64±0.14*

ACC1

Acetyl-CoA carboxylase 1

1.060.31

0.8660.18

FAS

Fatty acid synthase

1.060.27

0.68±0.17*

GPAM

Glycerol-3-phosphate acyltransferase

1.060.10

0.74±0.18*

MTTP

Microsomal triglyceride transfer protein

1.060.11

0.9460.17

PLTP

Phospholipid transfer protein

1.060.32

0.68±0.21*

Fatty acid biosynthesis

Triglyceride metabolism

Cholesterol Metabolism
SREBP-2

Sterol regulatory element-binding protein-2

1.060.18

1.1260.25

HMGR

Hydroxy-methylglutaryl-coenzyme A reductase

1.060.16

0.84±0.07

LDLR

Low density lipoprotein receptor

1.060.43

0.62±0.08*

CD36 (FAT)

Fatty acid translocase

1.060.52

0.6960.29

Animals were treated as described in Methods.
All values are expressed as the mean 6 SD; n = 6–7.
* p,0.05 compared with HFD mice.
Abbreviations: HFD, high fat diet.
doi:10.1371/journal.pone.0103621.t001
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Table 2. Relative Hepatic mRNA Expression Involved in Inflammatory Responsesin in Mice Fed on a HFD with or without 25HCDS.

Gene Name

Gene description

HFD (n = 6)

HFD+25HCDS (n = 7)

PGC-1a

Peroxisome proliferator-activated receptor gamma coactivator-1a

1.060.27

2.11±0.82*

PPARc

Peroxisome proliferator-activated receptor gamma

1.060.42

1.2760.52

IkBa

Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor a

1.060.25

1.35±0.27*

TNFa

Tumor necrosis factor a

1.060.28

0.50±0.21**

IL1a

Interleukin 1a

1.060.35

1.0260.20

IL1b

Interleukin 1b

1.060.21

0.64±0.16**

Animals were treated as described in Methods.
All values are expressed as the mean 6 SD;
* p,0.05,
** p,0.01 compared with HFD mice.
Abbreviations: HFD, high fat diet.
doi:10.1371/journal.pone.0103621.t002

25HCDS on lipid biosynthesis were summarized in Fig. 3. After
addition of 25HCDS, the cells were cultured for 6 hrs and with
[1-14C] acetate for an additional 2 hrs. Total lipids were extracted
and partitioned. The 14C-lipids in the chloroform phase as
decreased significantly in a concentration-dependent manner and
increased slightly in the methanol phase as shown in Fig. 3A. The
results indicate that neutral lipid biosynthesis has been suppressed.
TLC analysis of lipid in chloroform phase showed that [14C]
cholesterol and [14C] cholesterol ester, were synthesized but [14C]
oxysterol was not detected (Fig. 3B). Free [14C] cholesterol was
found significantly decreased following addition of 25HCDS
(Fig. 3B). The decrease was concentration dependent (Fig. 3B).
The decreased amounts of [14C]cholesterol bands on the TLC
were confirmed by HPLC analysis (Fig. 3C). The effect of
25HCDS on suppression of cholesterol biosynthesis is slightly
stronger than that of 25HC3S [19].
To investigate how 25HCDS inhibits lipid biosynthesis, total
RNA was isolated from the 25HCDS-treated HepG2 cells. The
mRNA levels of ACC and FAS for triglyceride synthesis, and
HMGCR for cholesterol synthesis were determined by real time
RT-PCR. As shown in Fig. 3D, 25HCDS decreased expression
of SREBP-2 and HMGCR in HepG2 in time dependent
manner. As shown in Fig. 3E and F, 25HCDS decreases
expression of SREBP-1c, and its response genes, ACC and FAS
(3E), and SREBP-2, HMGCR, and LDLR mRNA levels (3F) in
concentration dependent manner. As indicated in other studies,
ACC-1, FAS are the target genes of SREBP-1 pathway, and
HMGR and LDLR are the target genes of SREBP-2. The trend in
expression of target genes was consistent with the decreases in
expression of SREBP1/2 (Fig. 3E and F). Similar results have
been observed in THP-1 macrophages and primary rat hepatocytes (data not shown). These results indicate that 25HCDS
decreases expression of key genes involved in lipid biosynthesis via
SREBP pathway.

fat diet was changed to normal chew diet three days before the
mice were sacrificed after overnight fasting. The liver weight had
no significant difference (data not shown). Serum lipid analysis
showed that the administration of 25HCDS significantly decreased
triglyceride and cholesterol levels by 15% and 20% respectively.
ALK, ALT and AST activities were also greatly decreased by
25HCDS treatment (Fig. 4).
To study the effect of 25HCDS on hepatic lipid metabolism,
hepatic lipid levels and related gene expression were determined.
As previously reported, HFD-fed increased triglyceride, total
cholesterol, free fatty acid, and triglyceride levels in the liver
compared to chow-fed mice (Fig. 5). These increases were
significantly reduced by 25HCDS administration by 25%, 20%
and 18% (p,0.05), respectively, as shown in Fig. 5.
Gene expression study showed that 25HCDS administration
significantly decreased the expression of key enzymes and
receptors involved in biosynthesis of free fatty acid, triglyceride,
and cholesterol (Table 1). Dysregulation of lipid metabolism is
frequently associated with inflammatory conditions. 25HCDS
treatment significantly suppressed the expression of TNFa and
IL1b, by 50% and 36%, respectively (Table 2). These results are
consistent with the liver functional assay where it shows that
25HCDS suppresses liver inflammatory responses and improves
liver regeneration as decreasing alkaline phosphotase (ALK)
activity in sera. Interestingly, 25HCDS increased expression of
PGC-1a by 2-fold in the liver. As a result, 25HCDS may regulate
lipid metabolism and inflammatory responses via LXR, PPARc
and PGC-1asignaling.

Discussion
The function of oxysterol sulfation has extensively been
investigated in our laboratories [11]. The first discovered oxysterol
sulfate, 25HC3S, functions in vitro and in vivo as a regulatory
molecule: decreasing cholesterol and triglyceride biosynthesis,
suppressing inflammatory responses, and promoting hepatocyte
proliferation [21,22,23,24,25,26,27,31]. 25HC3S is biosynthesized
by CYP27A1 and SULT2B1b [20]. The present work has shown
that 25HC3S can be further sulfated to be another novel
cholesterol metabolite, 25HCDS. It has been reported that
SULT2A1 is able to sulfate hydroxyl group(s) on the side-chain
in oxysterol molecules with much less specificity than SULT2B1b
and be able to synthesize oxysterol disulfates [32]. It is reasonable
to propose that 5-cholesten-3b, 25-diol disulfate (25HCDS) is
biosynthesized from cholesterol by CYP27A1 to form 25hydroxycholesterol (25HC), sulfated by SULT2B1b to form 25-

Effects of 25HCDS on Lipid Homeostasis and
Inflammation in HFD-fed Mice
To study the effects of long-term treatment of 25HCDS on lipid
homeostasis, 10-week-old C57BL/6J female mice were fed with a
HFD for 10 weeks, and then, randomly divided into two groups:
25HCDS or vehicle treatment respectively by peritoneal injection
twice a week for six weeks. During the treatment, the mice were
fed with HFD, and body weights and caloric intake were
monitored (no significant difference, data not shown). To decrease
variation of serum lipid profile, after 6 weeks’ treatment, the high
PLOS ONE | www.plosone.org
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Figure 6. Biosynthetic pathway of 25HCDS. Cholesterol is hydroxylated by CYP27A1 in the mitochondria to 25HC, which is subsequently
sulfated at the 3b-position by SULT2B1b to form 25HC3S and further sulfated at the 25-hydroxyl group by SULT2A1 in cytosol to synthesize 25HCDS.
doi:10.1371/journal.pone.0103621.g006

hydroxycholesterol 3-sulfate (25HC3S), followed by furthersulfated by SULT2A1 to generate 25-hydroxycholesterol di-sulfate
as illustrated in Fig. 6. Further experiments are needed to confirm
the pathway.
The process of 25HCDS biosynthesis, oxysterol sulfation, may
represent a novel regulatory pathway, which mediates nuclear
receptor activities in hepatocytes. When intracellular cholesterol
levels are increased, mitochondrial cholesterol transport protein,
StarD1, delivers cholesterol into mitochondria, where regulatory
oxysterols, such as 25HC and 27HC, are synthesized by CYP27A1
[20,33]. These oxysterols in turn activate LXR, and subsequently
up-regulate expression of its target genes involved in cholesterol,
fatty acid, and triglyceride biosynthesis [6,34,35,36]. In addition,
25HC activates LXR, down regulates newly synthesized cholesterol biosynthesis by inhibiting HMGR expression and increases
ABCA1 mediated cholesterol secretion from the cells (HDL
formation). Oxysterols can be further sulfated to form oxysterol
sulfates, such as 25HC3S and 25HCDS, which inactivate LXRs,
suppress SREBP-1c processing, indicating that these sulfated
oxysterols decrease intracellular lipid levels by inhibiting their
biosynthesis. It is well known that the alternative pathway of bile
acid biosynthesis involves the transporting of cholesterol into the
mitochondria where the cholesterol is hydroxylated and then
converted to bile acids. However, the recent reports that oxysterols
and oxysterol sulfates generated by this pathway play an important
role in lipid metabolism, inflammatory responses, and cell
proliferation, indicating that this pathway is far more than only
cholesterol degradation or bile acid biosynthesis [11]. It has been
reported that 7-ketocholesterol can be sulfated to be 7-ketocholesterol 3 sulfate [37]; 24-hydroxycholesterol, 24-hydroxycholesterol 3-sulfate [32]; 24,25-epoxycholesterol, 24,25-epoxycholesterol 3-sulfate; cholesterol, cholesterol sulfate. Cholesterol sulfate
has been reported to inhibit gluconeogenesis [40] but 25HCDS
does not (data not shown). Furthermore, the effects of oxysterols or

PLOS ONE | www.plosone.org

sterols are completely different to those of the sulfated ones,
indicating that intracellular oxysterol or sterol sulfation represents
a novel regulatory mechanism involved in many biological
events.The liver plays a pivotal role in the maintenance of lipid
homeostasis. Accumulation of lipids in liver tissues leads to
nonalcoholic fatty liver diseases (NAFLD). The spectrum of
NAFLD ranges from simple non-progressive steatosis to progressive nonalcoholic steatohepatitis (NASH) that results in liver
cirrhosis and hepatocellular carcinoma [38]. The accumulation of
triglycerides and associated lipids and the occurrence of liver
inflammation in the hepatocytes are believed to be the major
pathogenic factors for the development of the diseases [39].
Lowering lipid levels is an important element of successful NAFLD
therapy. However, there is no approved treatment for NAFLD
currently. The discovery of the novel cholesterol metabolites,
25HC3S and 25HCDS, which decrease intracellular lipid levels,
has laid the groundwork for the development of the better
therapies.
The present study shows for the first time that the cholesterol
metabolite, 25HCDS, inhibits SREBP-1c/2 expression and
activity in vitro and in vivo; increases PPARc and PGC-1a
expression. It is well-documented that SREBPs control lipid
biosynthesis, PPARc regulates inflammatory responses, and PGC1a controls energy homeostasis. Thus, the results provide evidence
that 25HCDS is a potent regulator, which plays an important role
in maintenance of hepatic lipid homeostasis and inflammatory
responses.
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